Record-Breaking Price Performance
On 21 April 2026, Asarfi Hospital Ltd’s stock price surged to Rs. 223.85, surpassing its previous 52-week high of Rs. 221.00. This new peak places the stock just 1.29% above its prior high, underscoring a strong upward momentum. The stock’s day change was a notable 2.01%, outperforming the Sensex’s 0.66% gain on the same day, despite a slight underperformance relative to its hospital sector peers by 0.33%.
The stock’s performance over various time frames highlights its market-beating returns. Over the past year, Asarfi Hospital Ltd has delivered an impressive 140.70% return, vastly outpacing the Sensex’s marginal decline of 0.46%. Year-to-date, the stock has gained 19.01%, while the Sensex has fallen by 7.25%. Even on shorter horizons, the stock has shown strength, with a 1-month return of 39.08% compared to the Sensex’s 6.05%, and a 3-month return of 37.33% against the Sensex’s negative 3.50%.
Technical Indicators Confirm Bullish Trend
Technical analysis supports the bullish sentiment surrounding Asarfi Hospital Ltd. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained buying interest. The overall technical trend shifted to bullish on 13 April 2026 at a price of Rs. 214.85, moving from a mildly bullish stance.
Key technical indicators such as MACD and Bollinger Bands are bullish on the weekly scale, while monthly indicators show mixed signals with mild bearishness in MACD but bullish Bollinger Bands. Immediate support is strong at Rs. 72.90, the 52-week low, while resistance levels have been surpassed, with the previous 52-week high of Rs. 221.00 now serving as a new benchmark.
Financial Strength and Quality Metrics
Asarfi Hospital Ltd’s financials underpin its stock performance. The company reported outstanding results in the quarter ending December 2025, with net sales reaching a quarterly high of Rs. 46.10 crores and profit after tax (PAT) growing by 59.5% to Rs. 5.42 crores compared to the previous four-quarter average. The return on capital employed (ROCE) for the half-year stood at a robust 18.55%, reflecting efficient utilisation of capital.
The company’s ability to service debt remains strong, with a low debt-to-EBITDA ratio of 1.96 times, indicating manageable leverage. This financial discipline is further reflected in the company’s capital structure, which is rated as good, and a low net debt-to-equity ratio of 0.40, signalling limited reliance on external borrowings.
Valuation and Growth Metrics
Despite the strong price appreciation, Asarfi Hospital Ltd maintains an attractive valuation profile. The price-to-earnings (P/E) ratio stands at 27 times, while the price-to-book value (P/BV) is 4.65 times. The enterprise value to capital employed ratio is a modest 3.61 times, suggesting reasonable valuation relative to the company’s asset base.
The company’s PEG ratio is notably low at 0.17, indicating that the stock’s price growth is not excessively high relative to its earnings growth. Over the past year, profits have surged by 161%, outstripping the stock’s 140.70% return, which supports the valuation metrics.
Long-Term Growth and Quality Assessment
Over the last five years, Asarfi Hospital Ltd has demonstrated healthy sales growth with a compound annual growth rate (CAGR) of 22.70%. However, operating profit growth has been more moderate at an annual rate of 14.76%. The company’s overall quality grade is assessed as average, with management risk and growth rated below average, but capital structure considered good.
Other quality indicators include an average EBIT to interest coverage ratio of 3.30 times, which is relatively weak, and an average return on equity (ROE) of 13.08%, which is modest. The company has no promoter share pledging, and institutional holdings remain low at 1.98%, reflecting a stable shareholder base dominated by promoters.
Market Capitalisation and Shareholder Structure
Asarfi Hospital Ltd is classified as a micro-cap company, with promoters holding the majority stake. The absence of pledged shares adds to the company’s financial stability and governance profile.
Delivery Volumes and Trading Activity
Recent trading activity shows increased delivery volumes, with a 1-month delivery change of 37.5% and a 1-day delivery change of 40.34% compared to the 5-day average. On 20 April 2026, delivery volume accounted for 80.77% of total volume, indicating strong investor participation in the stock’s recent rally.
Summary of Key Financial and Market Metrics as of 21 April 2026
Price: Rs. 223.85 (All-time high)
52-Week Range: Rs. 72.90 – Rs. 221.00
Market Cap Grade: Micro-cap
Mojo Score: 82.0 (Strong Buy, upgraded from Buy on 13 April 2026)
P/E Ratio: 27x
P/BV: 4.65x
EV/EBITDA: 15.24x
ROCE (Half Year): 18.55%
Net Profit Growth (Dec 2025 quarter): 29.05%
PAT Quarterly Growth: 59.5%
PEG Ratio: 0.17x
Debt to EBITDA: 1.96x
Delivery Volume (20 Apr 2026): 21,000 shares (80.77% of total volume)
Conclusion
Asarfi Hospital Ltd’s stock reaching an all-time high on 21 April 2026 is a testament to its strong financial results, disciplined capital management, and sustained growth trajectory. The company’s market-beating returns over the past year, combined with solid quarterly performance and attractive valuation metrics, highlight a significant achievement in its market journey. While some long-term growth metrics suggest moderate expansion in operating profit, the overall financial health and quality indicators support the stock’s current elevated valuation and bullish technical trend.
